Jay Bradner, M.D.
@jaybradner
Followers
22K
Following
5K
Media
411
Statuses
3K
Physician-scientist making medicines with friends, memories with family. EVP R&D at Amgen
Joined September 2011
Today in @ScienceMagazine, together with my former colleagues at NIBR, we report the discovery and characterization of first molecular glue degraders of the WIZ transcription factor (TF) for fetal hemoglobin derepression and therapeutic consideration in Sickle Cell Disease. 1/10.
17
134
710
Bob Bradway announced today that I have joined his leadership team as Executive Vice President of R&D, and Chief Scientific Officer @Amgen. I am overjoyed by the opportunity to create and develop therapeutic solutions for patients with serious illnesses. Here are some additional.
We’re announcing two changes to Amgen’s senior leadership team that will keep our company at the forefront of innovation. @jaybradner, M.D., joins as EVP, R&D, and Chief Scientific Officer. David M. Reese, M.D., will assume a new role as EVP and Chief Technology Officer.
97
31
577
When I joined NIBR 7 years ago, my beloved predecessor Mark Fishman wisely said: "For things to remain as good, things will surely have to change." This rings true today as I share news that I will step down as President of NIBR on Oct 31. Read more: 1/7.
44
36
449
As seen driving in for morning rounds on the stem cell transplant service at @DanaFarber. Honk honk, and congratulations.
3
13
451
Not the first breakfast we’ve talked about CRISPR, but for sure the first explaining the Nobel Prize. Love that our girls will forever have two women as their frame of reference.
4
18
437
A gem for those who still debate academia “versus” industry. The present reality is that all in industry were once in academia, as trainees or scholars, and many in industry will return to teach, advise, investigate. The era of the One Way ticket is firmly over, buy the bus pass!.
Traversing industry and academia in biomedicine: the best of both worlds? #Viewpoint by Gary Gilliland @fredhutch, Aviv Regev .@genentech, Eric Schadt @sema4 & @joyceytung @23andMe
10
65
347
Excited to welcome @HowardYChang to @Amgen as our new SVP for Research & CSO! A pioneering physician-scientist, Howard’s expertise in genetics, oncology, & inflammation will help us push the boundaries of discovery. We’re excited to embark on this journey together to redefine the
20
26
312
The only barrier to biomedical innovation in Cambridge is the Cambridge-Allston Exit on the Mass Pike.
15
34
280
Devastated by the passing of Jose Baselga. A champion of cancer research, a passion for people and life, a brilliant light out far too soon. Rest in peace, Jose, we will miss your joy and your tireless ambition to do more for cancer patients.
6
17
277
Maybe the most lovely reflection on a life well lived, amidst a cancer diagnosis, that I’ve ever read. By Simon Boas.
6
61
276
Bringing some of our most important work home - developing top female scientific talent. #WomenAndGirlsInScience #TwinsAtTheScope
5
17
252
Good news today, passed the Hematology Board Exam. After so long away from the clinic, the preparation was amazing. 30+ new medicines in our discipline, from many friends and our own work at NIBR. Hope this credential is of reassurance to patients on the transplant wards.
28
1
248
Delighted that our home-grown, RNA-targeting (small-molecule!) splice modulator for #HuntingtonsDisease has been granted Fast Track designation, accelerating development & review of this potential first-in-class, molecular glue for HD.
7
35
233
With a chemical biology mindset, truly nothing is undruggable. Here, the active state of KRAS via modified Cyclophilin A ligands. Have been looking forward to seeing this in print. Congratulations, RevMed.
1
39
235
Today we announced a commitment to donate up to 130 million doses of hydroxychloroquine to support the global #COVID19 pandemic response. 1/5.
6
37
230
Here we report the mechanism of a sequence-specific, low molecular weight, RNA targeting splice modulator; with Fast Track designation late last year for clinical study in #HuntingtonsDisease. @NatureComms
3
34
220
The genius of appointing @eric_lander is not leading OSTP, but having him on the Cabinet. Eric is a commanding force of reason, judgement and strategy. He is also not a stay in your lane kind of guy, so I will sleep better at night knowing he is at that table.
BREAKING: Genome-sequencing pioneer Eric Lander to lead science policy for Biden
3
15
226
Everyone vs. COVID-19. Glad to share word of our committed effort to develop first intentional medicines for #Coronavirus targeting the main protease (Mpro). Thanks to our collaborators @DanNomura, Andy Plump and to @lisamjarvis @cenmag for your interest.
7
60
220
Today’s first approval of a CRISPR therapeutic is a milestone for the technology innovators, but also for the biologists who directed the machinery. Congratulations Stu Orkin, @bloodgenes Vijay Sankaran and colleagues!
2
39
209
Direct inhibition of transcription factors remains a high hanging fruit in therapeutic science, but avails a chance to rewire pathologic cell states. Just delighted to see this master class in drug hunting finally disclosed and published. So hopeful that IAG will help patients.
5
27
201
Delighted to announce our new training program in drug hunting. The Innovation Postdoc Fellowship comes with an all-access pass to NIBR, and first-class training in the science of therapeutics and translational medicine. Elite science meets entrepreneurial ambition. Learn more:.
2
72
192
Today we announced a remarkable new project with the @gatesfoundation to devise a potential in vivo gene therapy for #sicklecelldisease—the goal being a one-time, curative treatment accessible to those affected by SCD in under-resourced countries.
10
26
195
Delighted to finally share this first chapter of NIBR discovery chemistry towards yet another "intractable" protein-protein interface: PCSK9-LDLR. Nothing is undruggable @NovartisScience.
1
30
197
An exciting update on our Cancer Cell Line Encyclopedia: Quantified proteome profiles for 375 cell lines in @CellCellPress. @NovartisScience
3
65
194
Have been in this room too long, or does the Spike protein look kinda like a Cheeto? @McLellan_Lab @ChesterCheetah
12
9
184
The power of total academic target clarity, a biotech platform at the ready, global scale in drug development, and responsive regulators. Thank you and congratulations @pfizer, @BioNTech_Group, @NIH and @US_FDA.
2
12
185
Delighted to see this work on the first inhibitor/degrader of the Werner Helicase (WRN), finally published. A genetically defined synthetic lethality, to be tested in the human model system of disease. Congratulations to all from NIBR who led this program.
2
30
182
New twist in protein degradation: Researchers report they may have found a way to leverage autophagy to potentially clear out toxic proteins involved in Huntington’s.
1
43
169
Just wrapped the NIBR portfolio review - 30 days, 300 programs, 5 platforms. The most ambitious program in science I've seen. All tradeoffs to deliver somebody's hope. A golden age for therapeutics.
0
5
166
When speaking of COVID morbidity & mortality, we should use the terms "unvaccinated deaths" & "unvaccinated hospitalizations." Reframing this way may help assuage vaccine hesitancy & stress the urgent need to address inequities in access, both critical for global herd immunity.
7
29
164
Thanks @DrChoueiri. Just a joy and a privilege to be back at the bedside with the @DanaFarber Bone Marrow Transplant service, esp at such a dynamic time for our field of stem cell medicine.
2
2
165
Northern Lights over Iowa this evening. A geomagnetic storm to defy the notion of Fly-Over States.
2
8
159
Congratulations, Bill, Peter and Gregg! This year’s Nobel Prize in Medicine celebrates elegant, fundamental research that promises real contributions to cancer care. via @nytimes.
0
25
156
So very honored and excited to welcome Dr. Alice Shaw to lead cancer drug development at NIBR. Alice, I have admired your work for years, and cannot wait to work together to bring the most ambitious research program in cancer medicine to patients around the world.
Top lead cancer drug researcher Alice Shaw bids adieu to academia, hello to Novartis $NVS.
2
10
160
Thank you for your message. I am out of the office today, with no email access. I will be returning when the fish get bigger.
5
0
152
In the future, cancer medicines will be innovated and approved agnostic to tissue origin or histology, rather by the causative genetic alterations. The future is now.
4
14
151
Welcome AMPLIFY, a new AI protein design tool from Amgen R&D. Here, we report a Protein Language Model that is efficient and accurate, and best of all is open-source for broad consideration and innovation. Now, labs worldwide can AMPLIFY their ambitions for iterative protein.
1
25
151
First academic seminar in years. Exchanging insights into molecular glues and drugging transcription factors with some of my scientific heroes at UCSF (Mission Bay is so stacked). Admittedly rusty but thrilling. Thanks @CardioOncology @UCSFCancer @kevansf et. al.
6
7
147
Our first in class therapeutic targeting the Helios transcription factor, here via TPD via molecular glues. New target in the IO landscape, oral therapy. All fingers crossed for anti cancer activity of this program in patients with advanced cancer.
1
16
143
I love this paper from @davidrliu and @eric_fischer, and further optimized ZnF tags are warmly welcome. Question for you two: in the abstract you speak to “problems with current degron tags”. Are there problems with dTAG? Seems fully orthogonal, small, insertable, works in vivo,.
Today in @Science_Magazine we report the laboratory evolution of compact degrons that enable targeted protein degradation triggered by an otherwise-inert small molecule, a multidisciplinary study that integrates organic chemistry, molecular glues, protein evolution, genome
7
18
150
More amazing news. Thrilled to share this milestone approval of our new targeted therapy. More than ten years in the making, this program was supported by countless internal NIBR champions. Congrats to all who carried this therapy through to patients.
BREAKING: Novartis receives FDA approval for a new treatment of HR+/HER2- advanced or metastatic breast cancer with a mutation. #NovartisNews.
0
20
141
Attention all Cysteines: the SF Bay Area is just not safe. Shokat, Wells, Taunton, Nomura and now Gray are coming after you. Congratulations, Nat. Just loved sitting next to you.@DanNomura @CarolynBertozzi @kevansf.
Welcome back to the bay!!.
1
10
138
An energizing call with the scientific leadership of the @gatesfoundation this evening. We have much work to do, but do take some solace that the brightest minds in science are organizing openly, effectively to respond to #COVID19.
3
12
134
Still can’t get over the irony that the best platform for myeloma therapy is an Ikaros degrader (lenalidomide) paired with a molecule that blocks protein degradation (bortezomib).
Multiple myeloma - frontline quad therapy validated in high quality Ph3 study: HR = 0.42. ASH - late breaking abstract!
6
12
129
DOSEDO! Together with @SchreiberStuart, we have innovated a structurally diverse and complex library of DOS molecules Encoded by DNA Oligonucleotides. Next we plan to open access to the scientific community. #OpenSource #DEL
2
26
126
Got fast biology? Try our dTAG system for target validation and MoA studies. Rapid, protein-selective loss - like chemical CRISPR
3
60
128
This pandemic took so much, and for many everything. But it gave some of us a chance to be better Fathers. Happy Father’s Day, all.
1
2
127
Welcome home, Ty. Already madly in love with this little guy.
11
1
121
Thrilled that our first in class inhibitor/degrader of the Werner helicase HRO761 has been disclosed at the AACR-NCI-EORTC conference in Boston. A genetically defined synthetic lethality in MSI-hi tumors, revealed biologically at NIBR more than seven years ago. A brilliant med.
2
7
114
At NIBR, we are training our computers in organic #chemistry, to realize the promise of #MachineLearning and Generative Chemistry in the pursuit of therapeutics for challenging targets. #AI
6
22
120
Energizing two days with the brilliant students and faculty @StanfordUChem and @Stanford_ChEMH trading insights into therapeutic modularity, molecular glues, chembio and careers. Better together. Thx for the shout-out @CarolynBertozzi, and most of all to rockstar hosts Hlib and
Excited to hear @jaybradner, @Amgen CSO, deliver a student-hosted seminar @StanfordUChem. Thank you for spending the day with our trainees 🙏
2
3
121
This weekend, Jennifer and I ride a reimagined @PanMass Challenge for @DanaFarber. A solitary, reflective ride honoring all who bravely and quietly fight cancer, supporting the search for clues and cures. #PMC2020
1
3
120
Activation of STING by intermolecular glues, from NIBR Chemical Biology & Therapeutics. Another terrific example of induced multimerization, akin to NLRP3 but here for complex activation. Stay tuned….
A new paper reports the discovery of compounds called NVS-STGs, which bind to the N-terminal domain of STING and act as a molecular glue to induce higher-order oligomerization and activation. Free to read link at
1
18
115
Honored to be included in @NatureBiotech’s translational researchers list, with so many I have admired for so long, and very glad our chemical probes from @DanaFarber & @Harvard have helped the scientific community
2
14
113
NIBR-Weston, aka the Bradner Academy Rock Room. Would love to see your #WFH pics. #ScienceFromHome
12
0
114
Happy Mother's Day to the kindest person I have ever known. And Happy Mother's Day to all in our community who balance science, medicine and family. You are the truest of heroes.
0
2
111
Amazing work from NIBR’s collaboration with @DanNomura & team @UCBerkeley introducing DUBTACs -- a new modality that *stabilizes* target proteins - thus a potentially new class of medicines targeting heretofore intractable proteins, out in @nchembio:
2
10
106
Gravely concerned about the earlier incidence and disproportionate and escalating mortality of Colorectal Cancer in young adults. Must screen earlier, systematically. Must understand and influence exposure (food, alcohol, other). What is needed @NCIDirector and @KimmieNgMD?.
✳️Colorectal cancer is now the leading cause of cancer related death among males aged 20-39 and 40-49 ‼️It was third among 20-39 age group last year. ✳️ Concerning trend is also seen in young women; CRC related death and will likely surpass breast cancer in near future @OncoAlert
7
19
117
Going after the undruggable has always been about “breaking the rules of what we thought would be druggable.” Learn more about the potential of TPD in @NatureNews, via @Scudellari: .
3
26
113
I have to agree with Ben Cravatt: “covalent ligands in #drugdiscovery are here to stay.” Remarkably detailed article in @cenmag on the century’s-long evolution of covalent drug development and where the field stands 👇
2
17
107
We are saddened by the loss of our dear friend and colleague Tom Marsilje. A brilliant scientist and passionate patient advocate, Tom led a life of service to help others battling cancer. His courage, kindness and grace are an inspiration to all of us at Novartis.
2
25
104
Is there an extended cut to this interview? I could listen to @SchreiberStuart all day long.
During #DrugDiscoveryDay @RLCscienceboss had an in-depth discussion with @arenabioworks co-founder @SchreiberStuart around small molecule drug discovery, AI in chemical biology, & new models of funding science. Watch this conversation & more On Demand:
4
7
106
The flag has been raised on our Cambridge campus to kick off #PrideMonth. We support our LGBTQ+ community and, now more than ever, are reminded of the importance of June’s celebration of diversity, inclusion and acceptance.
2
6
99
Are we over-invested in cancer R&D? A gut-check moment for our industry, considered in my blog post here #AACR18
13
52
106
Today we reviewed the Novartis Development portfolio and strategy in Basel. What a privilege to examine the contributions of such visionary researchers, and to imagine the good that may someday soon come from this work. What a time and place to be a scientist.
3
0
110
The Cancer Dependency Map, a new open source browser from the @BroadInstitute nicely including NIBR datasets. Dig in! #AACR18
0
46
104
Spontaneous dinner with some Bradner Lab legends last evening in Kendall - now scholars, inventors, biotech leaders, professors, PhDs. More amazingly still just very close friends. Love you guys.
1
0
101
Reflective on last week's 50th birthday, it's pretty incredible that in my birth year the first full nucleotide sequence of a protein coding gene was published. And today we engineer chimeric proteins to rewire stem cells as curative therapeutics.
10
4
103
Saturday morning SCIENCE. Today we learn about Sea Turtles (coincidentally my favorite animal).
2
1
105
Today we post an internal, comprehensive study of AAV9-GFP tropism in NHPs with IT administration. DNA, RNA & protein detection reveal robust expression in lower motor neurons, but surprisingly not in neurons in higher cortical structures. Reflections, implications welcomed.
5
20
105
My daughters brought home this toy, and I can’t stop thinking about degrading it.
7
0
99
To improve CART access, durability, stemness and cost of goods, we created and developed YTB323, published today in Cancer Discovery. Kymriah mfg ripped to the studs and rebuilt, a true next-gen 1 day CART platform.
1
18
101
6
0
98
Leaves changing, heart pounding. PMC Unpaved charity gravel ride in The Berkshires for @DanaFarber. Moving to ride with DFCI heroes and patients, NIBR scientists and new friends. @PanMass
4
1
98
Tonight the Moon, Saturn and Jupiter all lined up above Star Wars at the Dreamland Drive-In on Nantucket.
2
1
99
“Consensus changing” chemical biology at its finest, a new approach to modulating gene control. Neormorphic covalent ligands redirect the intently studied FOXA1 transcription factor, and instruct on pioneering functionality. A first TF-DNA glue? Way to go @Michael_A_Erb and Ben.
Together with the Cravatt group, we have a new manuscript out reporting the chemoproteomic discovery of covalent FOXA1 ligands that bind its DNA-binding domain, corrupt its motif preferences, and redistribute it on the genome. 1/11
5
12
96
As a postdoc with @SchreiberStuart I was obsessed with the aggresome - but pivoted to gene control as an investigator. Still follow that literature, though, and this here is a nice story about aggresome biology and protein homeostasis in HSCs.
2
1
100
Geneticists stole cancer from the Pharmacologists. We (chemical biologists) are stealing it back.
5
11
97
Until the eventual worldwide availability of definitive antivirals and safe, effective vaccines, COVID patients are stabilized & treated with a battery of established generic medicines. Proud we now make a key set of 15 available to developing countries without any profit motive.
1
10
96
Not a cloud in the sky, or in the labs, at NIBR San Diego this week. A technological assault on tough targets, drug hunters’ paradise.
1
1
92
A brave, beautiful and deeply personal experience at the intersection of genotyping and identity, by the incomparable @SchreiberStuart in @HarvardMagazine.
3
36
101
Happy Father’s Day, always bitter and sweet, honoring our Dads by being the best we can for our kids.
0
0
97
Gravity-changing advance from @IsomorphicLabs and @GoogleDeepMind on AI-enabled drug discovery. Entering the "AlphaFold 3" era, now with protein-protein, protein-DNA and small molecule capabilities (also markedly improved primary structure prediction). The rising tide is just.
4
17
101
Proud to share our new research suggesting that protein networks in our blood communicate between organs, tissues and cells to regulate disease. More on the study, new published in @ScienceMagazine
2
36
94